Avellino, a leader in precision medicine, is making a global impact in genetics
and bringing innovative diagnostics, therapies, and AI-driven data processing to
patient care.
AvaGen is the the first and leading
personalized genetic eye test. AvaGen
quantifies the risk or presence of
keratoconus and other corneal
genetic disorders caused by
gene variants.
The Avellino SARS-CoV-2/COVID-19
Test (AvellinoCoV2) is a non-invasive,
swab based test used to detect the
SARS-CoV-2 virus.
Our mission is to bring personalized medicine to eyecare
professionals by delivering actionable information derived
from the unique genes of individual patients.
Avellino collaborates with best-in-class partners to create first-in-class
genetic tests and gene-editing therapies. These collaborations
provide the chance to integrate precision medicine into existing
healthcare practices and ultimately improve them.
Data must be straightforward for precision medicine to be properly
integrated into clinical care. Avellino provides multiple layers of
support in the patient treatment process to assist the clinician with
interpreting results, explaining results to patients, delivering
personalized treatment, and improving patient outcomes
At its very core, precision medicine begins with genetics. Tailoring
treatment relies on recognizing individual characteristics and a
patient’s unique susceptibility to certain diseases. For Avellino,
providing real genetic data that correlate with those susceptibilities is
the key.
Avellino is building upon the success of its own proprietary Universal
test, the world’s first DNA test confirming the presence of genetic
indicators positively associated with corneal dystrophies. Our latest
preemptive diagnostic tool, AvaGen, addresses keratoconus in
addition to corneal dystrophies, and is set to expand to address Fuchs’
dystrophy, glaucoma, and a wide range of other eye diseases in the
near future.
